Trial Profile

A Multicenter, Single-arm, Open Label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily LNP023 in Adult aHUS Patients Who Are Naive to Complement Inhibitor Therapy

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 05 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Iptacopan (Primary)
Indications Atypical Haemolytic Uraemic Syndrome
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms APPELHUS
Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals

Most Recent Events

03 Feb 2025 Planned End Date changed from 6 Jan 2026 to 29 Mar 2029.
03 Feb 2025 Planned primary completion date changed from 23 Dec 2025 to 19 Sep 2028.
15 May 2023 Planned End Date changed from 2 Jan 2026 to 6 Jan 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com